SHENZHEN-WOODY-VAPES
31.5.2022 18:00:06 CEST | Business Wire | Press release
ICCPP launched the full-range ceramic coil solution including disposable ceramic coil at Vaper Expo UK in Birmingham on May 27, 2022 -- a new category empowered by its "Digital Transformation" strategy, marking a new era in the global vape industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220528005017/en/
For the first time, ICCPP exhibited as a group and showcased its branded ODM+ solution and full-range ceramic coil solution. Adopting the Gene Tree technology, ICCPP’s ceramic coil will be integrated with the ODM+ business to promote a greater evolution in the industry. The ceramic coil, ICCPP’s first product released since it jointly launched the digital strategy with SAP and PwC, is bound to become a benchmark in the global vape industry.
Breakthrough: ceramic coil solution for disposable and multiple categories
In the vape industry, the ceramic coil technology is a key indicator of technological advancement of a company. ICCPP began to engage in the ceramic coil technology in 2019 by forming a R&D team led by "Peacock Program" talents, aiming to achieve an industry-leading level with the third or fourth generation of ceramic coil, and fully surpass the peers with the fifth or sixth generation.
Committed to becoming the leader in atomization technology, ICCPP brings a natural and pleasant vaping experience to the customers with its nanocrystalline (NC) materials and technical innovation. From thick film to thin film, from wire heating and surface heating to solid heating, ICCPP’s NC ceramic atomization technology has been constantly optimized the data model of the coil and enhancing the team's R&D strength to address the pain points in the vape coil industry. The newly launched Gene Tree thin film technology features five technical advantages, namely powder-free, improved safety, finer atomization, a longer lifespan, and an improved flavor.
As a result of the continuous endeavor of the R&D team, ICCPP recently launched the new generation of Gene Tree film technology and product applications, which, compared to the third-generation ceramic coil, has improved the flavor, increased the coil lifespan, and improved product reliability, bringing users a natural and pleasant vaping experience.
ICCPP will soon launch a disposable product equipped with the Gene Tree ceramic technology, with such features as longer-lasting flavor, more puffs, better restoration of flavor, and higher reliability, will bring revolutionary user experience, trigger a revolution in the industry, and become an industry milestone.
"Digital + technological innovation " to provide ODM + digital solution
ICCPP’s core advantages at the technical level are derived from its huge investment in scientific and technological innovation. On May 26, ICCPP announced the official launch of the "Digital Transformation Project" at its Shenzhen headquarters, becoming the world's first major company in the vape industry to cooperate with SAP and PwC. This marks that ICCPP will lead the industry into the phase of digital transformation.
The digital strategy refers to the overall digital innovation of the company integrating R&D, manufacturing, export, overseas marketing, etc. In the future, ICCPP will create an unprecedented "digital closed loop" and new digital competitiveness by creating digital R&D, digital manufacturing, digital marketing, and digital consumer experience. The mode of “digital + technological innovation” will become ICCPP’s underlying competitive advantage, including digitization + chips, digitization + fragrance, and digitization + smart manufacturing. "The company will drive development through digitalization and create new value through digitalization." Through digital transformation, the company aims to bring greater contributions to the industry and global consumers.
In order to develop ceramic coil, ICCPP quickly simulated the atomization effect by setting a data model and inputting parameters such as interface and size, so as to find the optimal configuration without sample production, thus accelerating product development and delivery. At present, ICCPP has a set of long-term plans for refillable and disposable ceramic coil products, and has reached cooperation intentions with at least 5 overseas major customers.
Mission of a leading going-out company: to empower global customers with technical innovation
ICCPP knows that customers in this era don’t need the traditional ODM anymore, but the branded ODM+. Therefore, the company has launched the new strategic partnership integrating brand positioning, user insight, product design, product development and after-sales, to guide customers to embrace new era of product customization.
Firstly, ICCPP promises to provide customers with the latest technology applications, and give them the same or even better technology as ICCPP’s own brands. Secondly, ICCPP shares all cutting-edge technologies with the entire industry chain in the strategic cooperation, including labs and institutes, automated factories, overseas user insights and global marketing services. This confidence of ICCPP comes from its rich and successful overseas experience and the ability to provide customers with one-stop services. ICCPP is committed to building two global platforms to empower customers: a truly open, Android-like vape technology platform, and a globalization platform based on years of overseas experience.
As the first strategic category after the digital upgrade, the ceramic coil solution can adapt to the full range of product lines. Emboding the industry's most advanced technologies, it is set to create a new vape category, improve user experience and bring changes to the market structure. On the one hand, ICCPP ODM+ business will undergo the digital upgrade and efficiency upgrade of the whole operation system integrating market survey, R&D, product design, order, delivery, and after-sales; on the other hand, it will establish in-depth cooperation with global customers on the ceramic coil solution. So far, ICCPP has reached cooperation intentions on this ceramic coil technology with many overseas major customers. ICCPP expects to bring more surprises to global customers and restructure the market in future.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220528005017/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom